See more : AUK Corp. (017900.KS) Income Statement Analysis – Financial Results
Complete financial analysis of PureTech Health plc (PTCHF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PureTech Health plc, a leading company in the Biotechnology industry within the Healthcare sector.
- ION Acquisition Corp 3 Ltd. (IACC) Income Statement Analysis – Financial Results
- Idorsia Ltd (0RQE.L) Income Statement Analysis – Financial Results
- Interactive Strength Inc. (TRNR) Income Statement Analysis – Financial Results
- Hannon Armstrong Sustainable Infrastructure Capital, Inc. (HASI) Income Statement Analysis – Financial Results
- Bankinter, S.A. (BKNIY) Income Statement Analysis – Financial Results
PureTech Health plc (PTCHF)
About PureTech Health plc
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.33M | 2.09M | 9.98M | 8.34M | 8.69M | 16.37M | 650.00K | 4.43M | 11.74M | 2.01M | 7.02M | 7.93M |
| Cost of Revenue | 4.93M | 152.43M | 110.47M | 0.00 | 85.85M | 77.40M | 71.04M | 1.57M | 740.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.60M | -150.34M | -100.49M | 8.34M | -77.16M | -61.03M | -70.39M | 2.86M | 11.00M | 2.01M | 7.02M | 7.93M |
| Gross Profit Ratio | -48.14% | -7,193.44% | -1,007.03% | 100.00% | -888.12% | -372.80% | -10,828.46% | 64.57% | 93.70% | 100.00% | 100.00% | 100.00% |
| Research & Development | 96.24M | 116.11M | 81.52M | 61.19M | 65.17M | 57.29M | 71.67M | 41.21M | 13.41M | 2.84M | 2.83M | 4.23M |
| General & Administrative | 25.18M | 35.67M | 30.76M | 26.50M | 34.89M | 24.43M | 46.28M | 37.16M | 18.38M | 7.17M | 3.55M | 3.77M |
| Selling & Marketing | 23.18M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 48.36M | 35.67M | 30.76M | 26.50M | 34.89M | 24.43M | 46.28M | 37.16M | 18.38M | 7.17M | 3.55M | 3.77M |
| Other Expenses | 0.00 | 48.12M | 47.98M | 40.19M | 44.03M | -278.00K | 14.00K | 46.00K | 448.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 146.95M | 199.90M | 160.26M | 127.87M | 144.09M | 120.39M | 116.07M | 78.36M | 55.38M | 19.46M | 10.10M | 13.98M |
| Cost & Expenses | 149.53M | 199.90M | 160.26M | 127.87M | 144.09M | 120.39M | 116.07M | 78.36M | 55.38M | 19.46M | 10.10M | 13.98M |
| Interest Income | 16.01M | 5.80M | 214.00K | 1.18M | 4.36M | 3.36M | 1.75M | 1.29M | 262.00K | 46.00K | 36.00K | 30.00K |
| Interest Expense | 13.49M | 3.95M | 4.71M | 2.95M | 2.64M | 392.00K | 553.00K | 801.00K | 835.00K | 2.59M | 367.00K | 609.00K |
| Depreciation & Amortization | 4.93M | 8.89M | 7.24M | 6.66M | 6.67M | 2.78M | 2.10M | 1.57M | 740.00K | 455.00K | 453.00K | 500.00K |
| EBITDA | -11.63M | -52.19M | -46.95M | 62.69M | 458.45M | -65.27M | -40.79M | -74.80M | -51.23M | -73.24M | -4.49M | -9.67M |
| EBITDA Ratio | -349.16% | -9,699.43% | -2,153.48% | -1,735.49% | -1,091.74% | -757.00% | -21,334.46% | -1,746.54% | -386.54% | -842.15% | -36.99% | -69.52% |
| Operating Income | -146.20M | -197.81M | -150.28M | -119.53M | -135.40M | -104.02M | -115.42M | -73.93M | -43.64M | -17.45M | -3.73M | -9.39M |
| Operating Income Ratio | -4,390.36% | -9,464.45% | -1,505.98% | -1,433.05% | -1,558.46% | -635.39% | -17,756.92% | -1,668.45% | -371.74% | -867.05% | -53.16% | -118.32% |
| Total Other Income/Expenses | 110.10M | 105.02M | 91.33M | 138.50M | 613.87M | 35.58M | 44.71M | -9.25M | -12.68M | -58.78M | -1.58M | -4.74M |
| Income Before Tax | -36.10M | -92.78M | -58.95M | 18.97M | 478.47M | -68.44M | -70.71M | -83.18M | -56.32M | -76.22M | -5.31M | -10.78M |
| Income Before Tax Ratio | -1,084.17% | -4,439.38% | -590.77% | 227.42% | 5,507.30% | -418.04% | -10,878.62% | -1,877.27% | -479.73% | -3,788.32% | -75.65% | -135.89% |
| Income Tax Expense | 30.53M | -55.72M | 3.76M | 14.40M | 112.41M | 2.22M | -14.00K | -1.57M | 1.92M | -278.00K | 274.00K | 535.00K |
| Net Income | -65.70M | -37.06M | -62.71M | 4.57M | 421.14M | -43.65M | 30.87M | -48.79M | -39.39M | -41.64M | -4.30M | -11.05M |
| Net Income Ratio | -1,972.88% | -1,773.40% | -628.41% | 54.77% | 4,847.42% | -266.65% | 4,749.08% | -1,101.15% | -335.55% | -2,069.73% | -61.31% | -139.36% |
| EPS | -2.38 | -0.18 | -0.21 | 0.02 | 1.49 | -0.16 | 0.11 | -0.21 | -0.21 | -0.51 | -0.07 | -0.16 |
| EPS Diluted | -0.24 | -0.18 | -0.21 | 0.02 | 1.44 | -0.16 | 0.11 | -0.21 | -0.21 | -0.51 | -0.08 | -0.16 |
| Weighted Avg Shares Out | 27.63M | 279.75M | 286.59M | 299.26M | 292.46M | 272.84M | 240.65M | 229.51M | 185.28M | 81.65M | 53.79M | 63.26M |
| Weighted Avg Shares Out (Dil) | 276.30M | 284.76M | 286.59M | 292.86M | 291.78M | 273.85M | 238.92M | 229.51M | 185.28M | 82.45M | 63.64M | 63.37M |
Source: https://incomestatements.info
Category: Stock Reports